Reporting on the generic drug market
197 articles in eight desks. Search every word of every piece, or browse by desk, topic and format. Every figure is cited inline to its source.
Desks
The GxRadar generic price index
We priced a fixed basket of 43 common generics every month since January 2014. By October 2026 the index stood at 47.4, down about 53 percent. How it works, and where it can mislead.
6 min read · 10 sourcesPrices & costs
What pharmacies pay, how prices are set and why they move.
Average manufacturer price, the confidential number behind Medicaid drug rebates
AMP is the price drugmakers report to Medicaid each month. It sets rebates, triggers inflation penalties and anchors federal payment caps, yet no single company's figure can be made public.
How pharmacy dispensing fees work
Medicaid pays pharmacies a per-prescription fee built from state cost surveys, mostly $10 to $11 in 2026. Medicare drug plans negotiate their own, which federal advisers describe as typically a fixed amount such as $1.
How the NADAC survey picks its pharmacies, and who answers
The monthly CMS survey behind NADAC: who is sampled, what invoices pharmacies send, why voluntary response made rates jumpy, how the 2024 moving average changed that, and how rate reviews work.
How the price of generic sildenafil 20 mg fell 92 percent
Federal NADAC data show a generic 20 mg sildenafil tablet fell from 65.9 cents in 2013 to 5.2 cents in 2026, mostly after 2016. FDA approval records for both sets of strengths, and a tadalafil comparison.
The 2024 NADAC swings, and the three-month average that followed
In 2024 the federal benchmark for generic drug costs lurched up and down across nearly every drug at once. Our basket index shows the swings month by month, and what changed when CMS switched to a moving average.
The cheapest pills in GxRadar's 47-drug price basket
Seven of the 47 generics we track cost pharmacies under 2 cents a unit in October 2026, led by amlodipine at 1.02 cents. Which drugs sit at the floor, how long they have been there, and what the ranking does not show.
The federal upper limit, Medicaid's ceiling on generic drug payments
The FUL caps Medicaid spending on generics at 175 percent of average manufacturer prices, or at pharmacy cost when that is higher. In October 2026 the pharmacy-cost floor set it for 59 percent of drug groups.
What happens to Medicaid spending when the first generic arrives
Federal research on prices after generic entry, and four worked examples from NADAC and Medicaid claims data: duloxetine, valsartan, rosuvastatin and tadalafil.
What pharmacies paid for gabapentin, 2013 to 2026
The pharmacy cost of a generic 300 mg gabapentin capsule fell from 5.6 cents in 2013 to a series low of 3.0 cents in September 2026, with a sharp rise in between. The NADAC record and the FDA approvals behind it.
What pharmacies paid for metformin, 2013 to 2026
A generic 500 mg metformin tablet has cost pharmacies about a cent and a half for 13 years. The NADAC record, what 730 tablets cost at that rate, and why the price has stayed so low.
What pharmacies paid for montelukast, 2013 to 2026
Federal NADAC data show the pharmacy cost of a generic 10 mg montelukast tablet fell 84 percent from 2013 to 2026. The year-by-year record, the 2012 generic launch and the 2020 boxed warning.
What pharmacies paid for omeprazole, pantoprazole and famotidine
Pharmacy costs for generic omeprazole and pantoprazole fell by more than half from 2013 to 2026. Prescription famotidine jumped 68 percent after the 2020 ranitidine withdrawal, then fell back below its 2013 level.
What pharmacies paid for simvastatin, 2013 to 2026
Federal survey data put a generic 20 mg simvastatin tablet at 2.7 cents in November 2013 and 3.2 cents in October 2026. The year-by-year record, the 2023 jump and the approvals behind the market.
What pharmacies paid for six generic antidepressants, 2013 to 2026
Federal NADAC data for sertraline, escitalopram, citalopram, fluoxetine, trazodone and duloxetine show three very different price paths since 2013, and FDA approval records help explain them.
What pharmacies paid for warfarin and clopidogrel, 2013 to 2026
Federal NADAC data show generic warfarin jumped in 2014 and never returned to its 2013 price, while clopidogrel, generic since 2012, lost more than half its price in two bursts.
What pharmacies pay for seven blood pressure generics, 2014 and 2026
At federal survey rates, 365 tablets each of seven common blood pressure generics cost pharmacies about $95 in October 2026, down from $1,403 in October 2014. One drug explains most of the drop.
Why drug prices change in January
Most drug list-price changes take effect Jan. 1, the day plan deductibles reset. Inflation rebates now push back on increases, and pharmacy cost data show no January jump for common generics.
Doxycycline's 2013 price spike and the decade-long fall that followed
In late 2013 pharmacies paid $3.36 for one generic doxycycline capsule. By October 2026 they paid 11 cents. What federal records say about the spike, and how slowly the price came back down.
How fast generic prices fell for rosuvastatin, duloxetine and tadalafil
Federal cost data show three widely used generics each fell more than 90 percent within 24 months of entry. One did it in five weeks. Month-by-month figures, lined up against FDA approval dates.
How NADAC is calculated
The CMS method behind NADAC, step by step: the monthly invoice survey, cleaning rules, simple averaging, weekly updates and explanation codes, plus what the comparison file shows about when rates move.
How pharmacies get paid for a prescription
Ingredient cost plus a dispensing fee is the starting formula. MAC lists, Part D price concessions and spread pricing shape what a pharmacy keeps, as federal rules and government reports document.
Levothyroxine and the price of a daily pill
Pharmacies paid 38.4 cents for a generic 50 mcg levothyroxine tablet in early 2015 and 4.0 cents in October 2026. The year-supply arithmetic, the FDA history behind the drug, and why NADAC is not what patients pay.
Nitrofurantoin and the antibiotic price story
Pharmacies paid $1.77 for a nitrofurantoin capsule in January 2014 and 28 cents in October 2026. How six oral antibiotics' prices diverged, why competition explains much of it, and where shortages fit.
The brand-generic gap in NADAC
In CMS's Oct. 28, 2026 cost file, brand tablets and capsules cost pharmacies a median 21 times the matching generic. For amlodipine the multiple was 857. Where the gap is widest, and where it nearly closes.
The economics of making a generic
What it costs to bring a generic to market and make it, how competition drives the price down, and why federal analyses find many launches unprofitable years later, using ASPE, FDA and NADAC data.
The generic price spikes of 2013 to 2015
Generic prices fell overall in the early 2010s, yet 315 established generics at least doubled in price. What GAO and HHS investigators found, what CMS price data show, and what Congress changed.
The generics that cost pharmacies more than they did in 2014
Most generics in GxRadar's 47-drug basket got cheaper. Seven cost pharmacies more than in January 2014, led by furosemide at 2.8 times its 2014 price. What federal cost and shortage data show, drug by drug.
The long deflation of generic prices
Of 43 common generics in GxRadar's NADAC series, 35 cost pharmacies less in October 2026 than in January 2014. Federal data show how competition drives that decline, and the rarer spikes.
WAC, AWP, NADAC, MAC, FUL and ASP compared
Six price benchmarks run through US drug payment, and none is what a patient pays. Who sets each one, what goes into it, where it is used, and how far apart they can sit for the same pill.
What NADAC measures, and what it leaves out
NADAC is the federal estimate of what retail pharmacies pay for a drug. Who publishes it, how the invoice survey works, how Medicaid uses it, and why it is not the price a patient pays.
What pharmacies paid for atorvastatin, 2013 to 2026
Federal survey data show the pharmacy cost of a generic 20 mg atorvastatin tablet fell from 18.3 cents in November 2013 to 2.8 cents in October 2026. The year-by-year record, and the FDA approvals behind it.
What pharmacies pay for a month of common generics
Thirty tablets of each of the 10 most-used generics we track cost pharmacies $35.70 in January 2014 and $8.80 in October 2026. That is acquisition cost, and the rest of the price sits on top of it.
Why generic prices fall as competitors enter
One generic maker cuts the brand price by about 39 percent; six or more cut it by over 95 percent. FDA's 2019 study, GAO data and GxRadar's NADAC files show how steep the curve is and why.
Why the same generic costs different amounts at different pharmacies
Cash quotes for the same three heart-failure generics ranged from $12 to almost $398 across 175 pharmacies in one 2016 study. Federal cost data show how little of that price is the drug itself.
Shortages
Why medicines run short, which ones are short now, and what to ask.
FDA's current drug shortages, by therapeutic area and dosage form
Of 69 drugs FDA listed as in shortage on Oct. 30, 2026, 49 were injections. Anesthesia, pain, IV nutrition and pediatric hospital drugs dominate, and the pills are mostly ADHD stimulants.
FDA's essential medicines list, and what happened to it
A 2020 executive order had FDA list the medicines the US must always have. HHS later cut it to 86, Medicare now pays for stockpiles of them, and a third of today's shortages are on the original list.
How FDA tracks drug shortages
What counts as a shortage under federal law, how manufacturers must warn FDA under section 506C, what the CARES Act added in 2020, and what FDA's shortage database showed on Oct. 30, 2026.
How FDA works to prevent drug shortages, and where its powers stop
FDA says it helped prevent 330 shortages in 2025 using early warnings, fast-track reviews, extended expiration dates and temporary imports. Its own reports show what those tools can and cannot do.
How long drug shortages last, measured on FDA's current list
The median drug on FDA's current shortage list was first posted 4.7 years ago. GxRadar sorted all 69 listings by age, form and reason, and checked what suppliers' recovery dates imply.
Lidocaine and bupivacaine, the local anesthetics that stay on FDA's shortage list
Lidocaine injection has been on FDA's shortage list since 2012 and bupivacaine since 2018. What the listings show, how FDA has patched supply, and why sterile numbing drugs keep running short.
Pediatric drug shortages
Seventeen drugs on FDA's current shortage list carry the agency's Pediatric tag. Most are hospital injections, four have been listed since 2012, and research shows what shortages like these have cost children.
The 'to be discontinued' entries on FDA's shortage list
FDA listed 161 drugs as to be discontinued in October 2026, more than twice its current shortages. Most are one maker's exit from one product, and discontinuations rarely start a shortage on their own.
The 2022 contrast dye shortage, when one Shanghai plant slowed CT scans nationwide
A lockdown shut the main US supplier's contrast plant in April 2022. FDA listed iohexol and iodixanol in shortage, allowed an unapproved import, and hospitals cut contrast use by as much as half.
The 2023 albuterol shortage, in the liquid hospitals use for nebulizers
FDA listed albuterol inhalation solution as in shortage in October 2022. A plant shutdown deepened it in 2023, and children's hospitals rewrote asthma protocols to use less of it.
The 2023 cancer drug shortage, from one plant to most US cancer centers
How the shutdown of one plant left most large US cancer centers short of cisplatin and carboplatin in 2023, what surveys and studies measured, how FDA refilled supply, and why carboplatin is still listed in 2026.
The 2024 IV fluid shortage
How hurricane damage to one North Carolina plant in September 2024 strained the US supply of IV fluids, what FDA and HHS did about it, and which fluids were still on FDA's shortage list in October 2026.
The amoxicillin shortage of 2022 and 2023
FDA declared a shortage of liquid amoxicillin on Oct. 28, 2022, during a surge of respiratory illness in children. What FDA said caused it, what it did, how prescribing shifted and what pharmacies paid.
The code-cart drugs on FDA's shortage list, from atropine to dextrose
Atropine has been in shortage since at least 2012, sodium bicarbonate since 2017 and 50% dextrose since 2022. In November 2025 one maker said it would stop making a set of emergency syringes.
The GLP-1 shortages and what they meant for compounding
How semaglutide and tirzepatide went onto FDA's shortage list in 2022, how they came off in 2024 and 2025, and why those dates set the rules for compounding pharmacies and outsourcing facilities.
The longest-running drug shortages
Six drugs on FDA's current shortage list have been there for more than 10 years. GxRadar ranked all 69 current listings by first-posted date and looked at what they have in common.
What to ask when your medicine is in shortage
How FDA publishes shortage information, what the agency can and cannot do about it, and the questions that help a pharmacist and prescriber work out the next fill.
Why antibiotics keep running short
Seven anti-infectives were on FDA's current shortage list in October 2026, one of them since 2015, and 30 more had discontinuation notices. Low prices and few makers explain much of it, federal research shows.
Why drug shortages happen
New US drug shortages fell from 251 in 2011 to four in 2025, yet old ones linger for years. FDA's 2019 root-cause analysis and later HHS research explain why cheap generic drugs run short and stay short.
Why sterile injectables dominate shortage lists
Injections made up 49 of the 69 drugs on FDA's current shortage list in October 2026, and their shortages ran longer. Sterile manufacturing, few producers and thin margins explain why, according to FDA and HHS.
Recalls & quality
Recall records, manufacturing rules and the cases that changed them.
Benzene in sprays, sanitizers and acne products, and the limits FDA set
Where benzene in some over-the-counter drugs came from, how FDA's 2 ppm and 20 mcg-a-day limits work, what its 2023 carbomer guidance asks, and what 100 recall records show.
CGMP and the rules behind drug manufacturing quality
What current good manufacturing practice requires under 21 CFR parts 210 and 211, how FDA inspectors check it, why data integrity matters, and what quality failures look like in FDA and openFDA recall data.
Data integrity in drug manufacturing
FDA's 2018 data integrity guidance, the ALCOA standard behind it, and how unreliable lab and production records turn into warning letters, import alerts and recalls.
Dissolution testing, the lab check behind many tablet recalls
How a dissolution test measures whether a pill releases its drug, how USP and FDA set the pass mark, and what 414 recall records citing dissolution show about which products fail.
Drug recalls by the numbers
GxRadar counted all 18,076 FDA drug recall records from mid-2012 to October 2026 by year, class, event and reason. A handful of giant recall events explain most of the swings.
FDA drug inspections by the numbers
FDA ran 1,248 drug quality inspections in fiscal 2025, and US plants drew the most serious grade more often than any region. Seven years of counts, outcomes by region, and what follows a bad result.
FDA inspections, Form 483s and warning letters
FDA ran 1,248 drug quality inspections in fiscal 2025 and judged 18 percent of them unacceptable. How plants are chosen, what a Form 483 is and is not, and how warning letters and import alerts follow.
How a carcinogen in blood pressure pills changed generic drug testing
Since 2018, nitrosamine impurities have produced nearly 500 federal recall records, pushed ranitidine off the US market and led FDA to set daily intake limits for impurities formed from the drug itself.
How drug recalls end
FDA decides when a drug recall is over. GxRadar read the rules and timed 3,654 closed recalls: the median took 504 days, and terminations have slowed sharply since 2024.
How drug recalls work
Who starts a drug recall, how FDA sorts recalls into Class I, II and III, how far down the supply chain a recall reaches, and what 18,076 enforcement records since 2012 show.
How FDA import alerts stop drugs at the border
FDA can hold drug shipments at the border without testing them. How import alerts and their red, yellow and green lists work, how many drug alerts are active, and how plants get on and off them.
How to check if your medicine was recalled
Where FDA publishes every drug recall it monitors, how to match a notice to your own bottle by NDC and lot number, and the questions that get a pharmacist to a quick answer.
How to read an FDA recall notice
A field-by-field reading of a real October 2026 Enforcement Report entry, what the recall classes and statuses mean, and how to check whether your own medicine comes from a recalled lot.
The 2008 heparin contamination
How a counterfeit ingredient called oversulfated chondroitin sulfate got into the US heparin supply, how FDA and CDC traced it, and what changed in oversight of drug ingredients afterward.
The 2020 metformin recalls and the NDMA found in extended-release tablets
How FDA testing found a probable carcinogen in some extended-release metformin in 2020, why the common immediate-release tablets were spared, and what 47 federal recall records show.
The 2023 eye drop recalls
How a drug-resistant bacterium in imported artificial tears sickened 81 people in 18 states, why FDA later warned against 26 store-label eye drops, and what changed for eye product makers.
The methanol hand sanitizer recalls of 2020 and 2021
How methanol got into hand sanitizer during the pandemic rush, why FDA put a whole country's sanitizer exports on import alert, and what 665 list entries and 89 recall records show.
The ranitidine withdrawal of 2020
How NDMA findings in ranitidine moved FDA from lot recalls in 2019 to a request in April 2020 that every maker pull the drug, and what the recall records and later research show.
The reasons drugs get recalled, counted from FDA's own records
A GxRadar count of 18,076 FDA drug recall records since 2012 shows a handful of failure types, led by sterility, manufacturing lapses, impurities and pills that dissolve out of spec.
The valsartan recall and what it did to prices
After FDA's July 2018 valsartan recalls, the national average cost of a 160 mg tablet rose from 9.5 cents to 37 cents in five months. Eight years later it is still above its pre-recall level.
What FDA's Class I drug recall records show
FDA put 1,753 drug recall records in its most serious class between mid-2012 and October 2026. GxRadar sorted them by year, event and reason to see what actually ends up there.
What FDA's Class II drug recall records show
Four in five drug recall records are Class II. GxRadar counted 14,602 of them by year, event and reason, and found manufacturing lapses on the rise and a second nitrosamine wave in 2025.
Which kinds of drug products get recalled most
Injectables fill the most drug recall records and tablets the most recall events. GxRadar sorted 18,076 FDA records by dosage form and route, and explains why the federal route field covers only one in six.
The generic drug scandal of 1989
How bribes and falsified data inside FDA's generic drug office led to criminal convictions, a collapse in approvals, and the 1992 law that lets FDA bar people from the drug industry.
How generics get approved
The FDA pathway from application to pharmacy shelf.
ANDA review goal dates and how often generics clear the first cycle
FDA meets its 10-month goal for acting on most generic applications, but only about one approval in five comes on the first review. How GDUFA goal dates work and what FDA's numbers show.
Complete response letters for generic drugs
FDA sends nearly two rejection letters for every generic it approves. What a complete response letter must contain, what FDA's own analyses say they cite, and why generic letters are not public.
FDA's Inactive Ingredient Database and the limits on excipients
A generic that uses more of an inactive ingredient than FDA's database lists can be refused at the door. What the Inactive Ingredient Database contains, how applicants use it, and where FDA says it stops.
Generic drug approvals in 2025, by the numbers
FDA counted 689 final generic approvals in fiscal 2025. GxRadar's calendar-year count from FDA's own database finds 648. What each total measures, what got approved, and the first generics FDA singled out.
Narrow therapeutic index drugs and the tighter test for their generics
Warfarin, levothyroxine, phenytoin and a few other drugs face a stricter generic test scaled to the brand's own variability. How it works, which drugs it covers and where state law adds rules.
New chemical entity exclusivity and the four-year door for generics
A drug with a never-approved active moiety gets five years in which no generic may even be filed, with an opening at year four for patent challengers. How NCE and three-year exclusivity work, and how to read the codes.
Orphan drug exclusivity and the generics it blocks
A rare-disease approval can bar copies of the same drug for the same use for seven years, patent or no patent. How the protection works, the court fight over its scope, and why generics often launch around it.
Pediatric exclusivity and the six months it adds before generics
A brand company that studies its drug in children at FDA's written request can win six more months of protection from generics. How the 1997 incentive works, what it attaches to, and what FDA's own lists show.
Pre-ANDA meetings and FDA's advice program for complex generics
Before filing, developers of complex generics can ask FDA for formal meetings. Which products qualify, what each meeting offers, how often FDA grants them, and how GDUFA IV would rebuild the program.
Q1/Q2 sameness, the recipe rule for generic injectables, eye drops and creams
Generic injectables and eye and ear drops must match the brand's inactive ingredients to within 5 percent. How FDA applies the rule, where it bends, and what a February 2026 law now makes the agency disclose.
Reference listed drug, reference standard and basis of submission, explained
Every generic copies one approved product and is tested against another, and they are often not the same pill. How FDA defines the RLD and the reference standard, and what the Orange Book shows for common generics.
Authorized generics are the brand drug under a generic label
How an authorized generic differs from an ordinary generic, why brand companies launch them during the first filer's 180 days, what the FTC found about prices and settlements, and how to read FDA's list.
Bioequivalence and the 80-125 rule
The 80 to 125 percent range is a statistical test on blood levels. It does not let a generic hold 20 percent less drug. How the test works, what FDA's May 2026 guidance says, and what 2,070 studies showed.
Complex generics and why some drugs still have few or no copies
Inhalers, peptide injections, creams and long-acting shots are hard to copy. What FDA counts as complex, how its product-specific guidances and pre-ANDA meetings work, and what recent approvals show.
How a generic drug gets approved
Every US generic goes through an Abbreviated New Drug Application. What goes into one, how FDA reviews it, the GDUFA III deadlines, and why a finished review can still end in a tentative approval.
How biosimilars differ from generics
Biosimilars and generics are approved under different laws and sameness tests. How the 351(k) pathway works, what interchangeability means at the pharmacy, and how many biosimilars FDA had approved by October 2026.
Tentative approval, when FDA clears a generic that cannot yet be sold
What a tentative approval is, why finished generic applications wait in that status for patents and exclusivity to lapse, and how the same tool supplies HIV drugs to PEPFAR.
The 505(b)(2) pathway, between brand and generic
How FDA's hybrid new drug application works, how it differs from a full NDA and a generic ANDA, and what three years of approval data show about who uses it.
The Orange Book explained
FDA's Orange Book lists every approved drug, the patents and exclusivities that delay generics, and which copies FDA rates as substitutable. How each section works, and what changed in 2021.
What FDA's yearly first generics lists show
FDA's 2025 first generics list has 91 entries, but one entry is not one medicine and approval is not launch. What the lists count, and what price data show after a first copy arrives.
What therapeutic equivalence codes like AB, AA and BX mean
The two-letter codes in FDA's Orange Book tell pharmacists which generics FDA rates as interchangeable with a brand. All 16 codes, the numbered AB1 and AB2 variants, and how state laws use them.
Competitive generic therapy, the FDA program for drugs with one maker
Since 2017 FDA can fast-track and reward generics of drugs with one or no generic competitor. The rules, the separate 180-day exclusivity, and what FDA's list of 531 CGT approvals shows.
FDA's product-specific guidances, the study plans behind each generic
FDA has published 2,447 product-specific guidances telling generic makers what studies it expects for a given drug. About 98 percent are still drafts. What they say, and why they matter most for complex products.
GDUFA, the user fees that pay for generic drug review
Generic makers will pay FDA about $666 million in fiscal 2027, including $375,684 per application. What the fees buy, how the program has changed since 2012, and where the 2027 renewal stands.
Inside FDA's Office of Generic Drugs
The FDA office that reviews every US generic approved 689 applications in fiscal 2025 and sent nearly twice as many rejection letters. How it is organized, what its numbers show, and how a review moves.
The Hatch-Waxman Act explained
The 1984 law traded a fast generic pathway for extra patent life and new exclusivity for brands. How each side of the deal works, how the caps are calculated, and what Congress has changed since.
Your medicine, explained
Labels, pill changes, generic vs brand, and using medicines safely.
Boxed warnings, FDA's most prominent label warning, explained
What 21 CFR 201.57 requires of a boxed warning, how many prescription labels carry one (about a third, by two counts 14 years apart), and why a generic's box matches the brand's.
Extended-release, delayed-release and immediate-release pills, and how FDA judges their generics
ER, XL, DR and the rest describe how a pill lets go of its drug. What the formulations are, how FDA tests generic copies of each, what the Orange Book codes say, and what our recall data show.
How to read a Drug Facts label
Every OTC medicine carries the same panel, in the same order, under a 1999 FDA rule. A heading-by-heading guide to 21 CFR 201.66, worked through on a generic ibuprofen 200 mg label.
Look-alike and sound-alike drug names, and how FDA tries to keep them apart
How FDA screens new drug names with its POCA software, why generic names can resemble each other, how tall man lettering works, and what recall records show about mix-ups.
Pill imprint codes and the 1993 rule behind them
Since September 1995, nearly every US tablet and capsule must carry a code identifying the drug, its strength and its maker. What 21 CFR 206 requires, who is exempt, and where imprint data live now.
Scored tablets and what the label says about them
Since 2013, FDA has reserved the phrase "functional scoring" for tablets tested to split evenly. Where that wording appears on a prescription label, what sits behind it, and how often it shows up in FDA's data.
The 1970 law behind child-resistant medicine caps
How the Poison Prevention Packaging Act of 1970 came about, how CPSC tests a child-resistant package, and what federal studies found about its effect on child poisoning deaths.
Unit-dose and blister packaging, from hospital carts to dose packs
How unit-dose systems spread through US hospitals, what FDA requires on unit-dose and blister labels, the six-month dating rule for repackaged doses, and how blister packs fail.
What 'USP' after a drug name means
The three letters point to a public quality standard that federal law makes binding. What a USP monograph covers, who writes and enforces it, and why the letters are the maker's claim and no seal of testing.
What "Rx only" on a drug label means
The symbol traces to a 1951 amendment and a 1997 rewrite of federal drug law. How a drug lands on either side of the prescription line, and how molecules from loratadine to naloxone crossed it.
What the storage instructions on a medicine label mean
How federal rules tie a label's storage line to its expiration date, what USP terms like controlled room temperature mean in degrees, and what FDA recall records show about storage failures.
Where the lot number and expiration date sit on a medicine package
What federal rules require of the lot number and expiration date, how they fit into the DSCSA 2D barcode, and why recalls are organized around them.
How drug expiration dates are set
What the expiration date on a medicine means under federal rules, how stability testing produces it, what the federal Shelf Life Extension Program found, and when FDA has allowed use past labeled dates during shortages.
How to dispose of unused medicines
The order of options FDA recommends, from DEA take-back sites and mail-back envelopes to the short flush list and household trash, and what each one accepts.
How to look up a drug on DailyMed
DailyMed is the National Library of Medicine's free archive of drug labels as companies submit them to FDA. How to search it by name or NDC, find inactive ingredients and imprints, and tell the leaflets apart.
How to read a prescription label
Which fields federal law requires, which come from your state, how the Rx number differs from the NDC, where lot numbers live, and the 12-digit NDC change set for 2033.
Medication Guides and patient package inserts
What 21 CFR Part 208 requires, when a pharmacy must hand over a Medication Guide, how patient package inserts differ, and where FDA's one-page replacement proposal stands.
State generic substitution laws
Whether a pharmacist must, may or may not swap in a generic is set by state law. How mandatory and permissive states differ, what consent and notice rules require, and where the Orange Book fits.
Store-brand OTC medicines
The two legal routes OTC medicines take to the shelf, what the 2020 CARES Act changed about monographs, why store brands carry the same active ingredients, and where to read Drug Facts.
The NDC number explained, from 10 digits to 12
The National Drug Code's three segments and three 10-digit formats, how it becomes 11 digits for billing, how to look one up, and FDA's 2026 rule moving every NDC to 12 digits in 2033.
The pharmacist's role in generic substitution
What a pharmacist checks before swapping in a generic: the Orange Book code, the prescriber's instructions, state rules for narrow therapeutic index drugs, and the counseling duty set by OBRA '90.
What a generic must share with its brand, and what can differ
FDA fixes a generic's active ingredient, strength, form, route and absorption. Fillers, dyes, shape and price can vary. How the rules work, and how to look up one product's ingredients on DailyMed.
Why your pill changed color
Pharmacies buy the same generic from different manufacturers, and each makes its tablet look different. How the required imprint code identifies a pill, and what research found about appearance changes and refills.
At the pharmacy counter
Cash prices, copays, insurance rules and help paying.
Copay accumulators and maximizers, and the rules that govern them
How plans can stop drug coupons from counting toward a deductible, what a 2023 court ruling changed, why generic equivalents matter, and where federal and state rules stand in 2026.
Early refills, vacation overrides and emergency supplies
Drug plans reject refills that come too soon, often until 75 percent of the last fill is used. How those edits work, the vacation and lost-supply overrides, disaster rules and state emergency-supply laws.
How the 340B drug pricing program works
The federal program behind $100 billion a year in discounted drug purchases: how the ceiling price is set, who qualifies, the contract pharmacy and rebate fights, and what it means at the counter.
How to appeal a drug coverage denial
The steps and deadlines for challenging a denied prescription in Medicare Part D and in private plans, from the first coverage request to independent review, with 2026 and 2027 dollar thresholds.
How to compare pharmacy cash prices for a generic prescription
A 2014 phone survey found one generic antibiotic priced from $5 to $229 in a single county. How to compare cash quotes by phone, and how to read them against NADAC.
How to transfer a prescription to another pharmacy
How pharmacists move a prescription between stores, what the new pharmacy needs, the federal limits on controlled drugs including a 2023 DEA change, and when a transfer will not work.
Medicaid prescription copays and the federal limits on them
Federal rules cap Medicaid drug copays at $4 for preferred drugs and $8 for others, indexed since 2015, with broad exemptions and a 5 percent household cap. A 2025 law adds required copays in 2028.
Medicare Extra Help: who qualifies in 2026 and what it costs
The 2026 income and resource limits for Medicare's Low-Income Subsidy, the copays enrollees pay for generics and brands in 2026 and 2027, and how to apply.
Preventive drugs that plans must cover with no cost sharing
The ACA requires most private plans to cover task force A and B items, including statins for some adults and HIV PrEP, at $0. The Supreme Court upheld the system in 2025; the panel has since been remade.
Specialty pharmacies, limited distribution and how they differ from the drugstore
Specialty pharmacy has no federal definition. What CMS and FDA documents do say, how limited distribution works, what specialty generics cost Medicare, and the 2029 network rule change.
State drug price transparency laws, and what they show
At least 30 states require drug price reporting. What the laws demand, what California's public reports show for generics, and the few rules that put prices in front of shoppers.
The Medicare Prescription Payment Plan, and what its first year of data shows
How Medicare's option to pay Part D drug costs in monthly installments works, worked examples of the billing formula, and GxRadar's tally of CMS's first-year 2025 data.
What a pharmacy benefit manager does
Three PBMs processed nearly 80 percent of US prescriptions in 2023, FTC staff found. How PBMs run drug benefits, how they are paid, and what a February 2026 law changes from 2028.
A script for talking to your pharmacist about price
Twelve specific questions to ask about the cost of a prescription, why each one helps, which ones belong with your prescriber, and the 2018 federal laws that let pharmacists tell you when cash is cheaper.
High-deductible health plans and generic drugs
The 2026 IRS limits for high-deductible plans, the 2019 notice that lets plans cover some chronic-condition drugs before the deductible, and how cash prices fit in while the deductible is unmet.
How prescription discount cards work
Free discount cards run on negotiated pharmacy rates and per-fill fees. When they can lower a cash price, why the purchase usually sits outside insurance and Medicare's cap, and which federal privacy rules apply.
How to ask for the cash price at the pharmacy
Two 2018 federal laws let pharmacists tell you when paying without insurance costs less. What the laws say, what pharmacies pay for common generics, and the questions that get you both prices.
Mail-order pharmacy basics
How mail-order pharmacies fill and ship prescriptions, the Part D rule that keeps 90-day fills available at retail, what two studies found about temperatures inside shipped packages, and the 2023 transfer rule.
Patient assistance programs, Extra Help and 340B, compared
Manufacturer programs, state pharmaceutical assistance, Medicare's Extra Help and health centers in the 340B program each help a different group. Current eligibility figures and how the pieces interact.
Prior authorization and step therapy
What prior authorization and step therapy are, the 2024 CMS rule that set 2026 decision deadlines but excluded drugs, and the Part D and marketplace rules that do cover prescriptions.
Tiered formularies explained
How plans sort drugs into cost tiers, why most generics land on the cheapest one, the federal rules for Medicare Part D tiers in 2026, and how a tiering exception request works.
Using an HSA or FSA for prescriptions
The 2026 HSA and FSA limits, why over-the-counter medicines have qualified without a prescription since 2020, and the account rules that differ from the medical deduction on a tax return.
When the cash price beats the copay
For many cheap generics the copay can be more than the drug costs. What a 2018 JAMA study found, what October 2026 NADAC benchmarks show, the two 2018 laws that ended gag clauses, and what to ask.
Why a 90-day fill often costs less than three 30-day fills
For cheap generics the dispensing fee can be most of the bill, and a 90-day fill pays it once. The arithmetic with October 2026 NADAC and Medicaid fee benchmarks, plus plan rules and when a long supply may not fit.
Medicare Part D changes in 2025, 2026 and 2027
The Part D out-of-pocket cap went from $2,000 in 2025 to $2,100 in 2026 and is set at $2,400 for 2027. How it is indexed, who pays in each phase, where generics fit, and the Extra Help amounts.
Law, patents & policy
Patents, competition law, Medicare and Medicaid.
Generics fill 84.5% of Medicare Part D claims and account for 11.6% of the cost
CMS grand totals for 2013 to 2024 show the generic share of Part D claims rising and the generic share of cost falling, plus a 2024 drop in generic spending that matches a pricing rule change.
Generics fill 86% of Medicaid prescriptions and take 11% of the spending
A GxRadar analysis of CMS State Drug Utilization Data, 2014 to 2025: generic share of Medicaid prescriptions and gross spending, how brands took over the dollars, and what rebates change.
How Medicare drug price negotiation works
Which drugs Medicare has negotiated, the first prices in effect since January 2026, the 2027 and 2028 rounds, and how a generic or biosimilar takes a drug out of the program.
Medicare Part B and Part D drugs compared
Which drugs Medicare covers under Part B and which under Part D, how the ASP-plus-6-percent payment works, what enrollees pay in 2026 and how Part B inflation rebates lower some coinsurance.
Most-favored-nation drug pricing, from the 2020 rule to the 2026 models
Tying US drug prices to what other rich countries pay failed in court in 2020 and returned by executive order in 2025. What exists now, its legal status, and why generics are mostly left out.
Pharmaceutical tariffs, and why generics were left out
A 2026 proclamation put tariffs of up to 100% on imported patented drugs and exempted generics for now. The Section 232 rates, the generic definition, and the April 2027 review date.
State generic drug price-gouging laws and the court fights over them
Maryland's 2017 ban on generic price gouging was struck down in 2018. Minnesota's was blocked in 2025. Illinois's is still in force. How each law works, why courts split, and what our price data show.
State prescription drug affordability boards
How state drug affordability boards review prices and set upper payment limits, which states have them, where Colorado's blocked cap and Maryland's first limits stand, and how generics fit in.
The 1938 Food, Drug, and Cosmetic Act
A 1937 elixir made with an antifreeze-like solvent killed 107 people, and Congress responded with the law that still governs US drugs. What it required, and why the solvent is still in FDA guidance.
The Durham-Humphrey Amendment of 1951
A 1951 law drew the federal line between prescription and over-the-counter drugs. What it said, how the Rx legend and switch rules changed, and why the line still shapes generics.
The Kefauver-Harris Amendments of 1962
After thalidomide, Congress made drugmakers prove their products work. How the 1962 law changed approval, and how its review of older drugs produced the first abbreviated applications for copies.
The Orphan Drug Act of 1983
A 1983 law gave rare-disease drugs tax credits and seven years of exclusive marketing. FDA counts 6,340 designations in its first 40 years. How it was built, amended, and where generics meet it.
What the 2026 federal PBM law changes, and what states did first
Congress wrote its first broad rules for pharmacy benefit managers into a February 2026 spending law. What each section does, when it starts, and how it fits with 50 states' worth of PBM laws.
What the FTC's study of pharmacy benefit managers found
The FTC ordered the largest PBMs to open their books in 2022. Two interim reports later, here is what staff found about specialty generic markups and pharmacy pay.
Paragraph IV certifications and the patent fights behind early generics
Every generic application must take a position on each patent the brand has listed with FDA. The rules behind the 20-day notice, the 45-day window to sue, the 30-month stay, and how these cases end.
180-day exclusivity for first generic filers
The first company to challenge a brand's patents with a generic application can win 180 days without later challengers. Who qualifies, what starts the clock, six ways to forfeit, and an August 2026 court ruling.
Citizen petitions and generic drug approval
Since 2007, a law has limited how citizen petitions can hold up generic approvals. FDA's reports to Congress show few delays, a steep drop in filings, and a steady complaint about the staff time involved.
Drug importation under section 804
What the 2003 law letting states import prescription drugs from Canada requires, how FDA's 2020 rule set it up, and where the first two state programs stood in late 2026.
Generic drug labeling, skinny labels and carve-outs
Why a generic's label must match the brand's, how section viii carve-outs create skinny labels, what the 2011, 2013 and 2026 Supreme Court decisions held, and which changes generics cannot make alone.
How 503A and 503B compounding pharmacies differ
The two federal frameworks for drug compounding, how the 2012 fungal meningitis outbreak led Congress to pass the Drug Quality and Security Act, and how FDA and state boards split oversight.
How Medicaid pays for generic drugs
Generics are 86 percent of Medicaid prescriptions and 14 percent of its gross drug spending. How the rebate program, the 2015 generic inflation rebate and Federal Upper Limits shape what Medicaid pays.
How Medicare Part D pays for generics
Generics are 90% of Part D prescriptions and about 12.5% of its gross spending. How plan bids, pharmacy contracts and the redesigned benefit decide who pays for a generic fill.
How the CREATES Act got generic makers access to brand samples
Generic makers need brand samples to test against. Safety programs called REMS let some brands refuse. How the 2019 CREATES Act changed that, and what FDA, the FTC and GAO have reported.
Patent thickets, evergreening and the Orange Book
How secondary patents pile up around brand drugs, which ones FDA lets companies list, what the October 2026 patent data show, and what regulators and courts did about improper listings.
Pay-for-delay settlements and what the FTC counts
How reverse-payment patent settlements work, what a 2013 Supreme Court decision changed, and what 18 years of FTC settlement filings show about the deals companies still make.
The Inflation Reduction Act and generic drugs
The 2022 law created Medicare price negotiation, a Part D out-of-pocket cap and inflation rebates. Each treats generics differently, and a generic launch is the main way a drug leaves negotiation.
Supply chain
How medicine moves from ingredient plant to pharmacy.
China's role in drug ingredients and the chemicals behind them
What FDA testimony, FDA site data and USP supply mapping show about China's share of US drug ingredients, from finished pills down to key starting materials.
Contract manufacturing in generic drugs, and who actually makes the pill
A third of the finished-dose plants FDA bills under the generic drug fee program make product only for other companies' approvals. The rules, the counts and what the label leaves out.
Counterfeit drugs and the US supply chain
Fake medicines are rare in US pharmacies but not absent. What FDA's recent counterfeit cases show, how the DSCSA is meant to catch them, and the agency's warnings about online sellers.
FDA drug establishment registration and listing, explained
Every plant that makes, repacks or relabels drugs for the US must register with FDA each year and list its products. What 21 CFR part 207 requires, what FDA's databases show and what registration does not mean.
Group purchasing organizations and hospitals
How hospital purchasing groups negotiate generic drug prices, the 1987 anti-kickback exception that lets vendors pay them, and what federal reports link to injectable shortages.
How a pill gets from the factory to the pharmacy
The physical and financial chain behind a generic prescription, from ingredient plant to pharmacy counter, and how few companies sit in the middle of it, according to federal reports.
How cold-chain medicines are kept in range, and what happens when they are not
The temperature bands, the federal rules for warehouses and distributors, what an excursion triggers, and 14 years of FDA recall records on temperature problems.
How hospitals buy drugs
Wholesalers, group purchasing contracts and the 340B program, how Medicare pays hospitals for outpatient drugs, and how hospital pharmacies cope with shortages, from federal sources.
Independent and chain pharmacies, by the numbers
About 19,000 independent pharmacies operate alongside chain stores. What the counts show, what a Health Affairs study found about closures from 2010 to 2021, and the Part D rules on distance to a pharmacy.
India's place in the US generic drug supply
What FDA and USP data show about how much US generic medicine comes from India, how FDA inspects Indian plants, and what the figures cannot tell you.
Pharmacy deserts, and what the closure data show
US community pharmacies posted a net loss of 3,062 stores from 2022 to 2024. How researchers define a pharmacy desert, who lives in one, and what peer-reviewed studies found when pharmacies close.
Repackagers and relabelers, the firms that put generics in new bottles
How federal rules define repackagers and relabelers, why their NDCs and expiration dates differ from the original, and what FDA's NDC and recall data show about them.
The Drug Supply Chain Security Act and drug serialization
The 2013 DSCSA set a 10-year path to electronic, package-level drug tracing. What a product identifier holds, who has to comply, and why small pharmacies now have until November 2027.
The federal push to make more medicine in the US, and where generics fit
Executive orders since 2020, a new API stockpile, an FDA review pilot and 2026 tariffs on patented drugs, with dates. Generic drugs and their ingredients remain exempt from the tariffs as of late 2026.
The Strategic API Reserve, the federal stockpile of drug ingredients
A 2025 executive order told HHS to fill a near-empty reserve of active pharmaceutical ingredients for about 26 critical drugs. What it holds, what it costs and what is still not public.
What drug wholesalers do
Three wholesalers move more than 90 percent of US drug distribution. For generics they also hold inventory, process hospital chargebacks and keep the package-level tracing records federal law requires.
Where generic drug ingredients come from
FDA counts the plants that make active ingredients and finished generics for the US, but not their output. What its testimony and quality reports show, how drug master files work, and what labels leave out.
Why some generics have only one maker
FDA lists 807 off-patent prescription products with no approved generic, and many older generics have one or two suppliers. What the counts show, what ANDA tallies miss, and why makers stay away.